|Bid||25.55 x 800|
|Ask||25.70 x 800|
|Day's Range||24.26 - 26.24|
|52 Week Range||2.52 - 33.00|
|Beta (5Y Monthly)||4.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.36|
Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that management will present at two upcoming investor conferences:
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109 for recurrent C. difficile infection (CDI). After obtaining highly statistically significant topline Phase 3 ECOSPOR III SER-109 study results in recurrent CDI, Seres requested a Breakthrough Therapy Designation meeting with the FDA. In response to the meeting request, the FDA reaffirmed its prior guidance regarding the efficacy requirements to support a SER-109 BLA submission, which were exceeded by the recent positive SER-109 Phase 3 study results, reaffirmed its prior guidance that at least 300 patients will be required for the safety database, and indicated there was not a reason for a meeting at this time.
While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...